Democrats in Congress have shifted their attention to lowering the cost of insulin, a narrow drug pricing reform policy goal after their agenda stalled earlier this year with the failure of the Build Back Better plan.

Senate Majority Leader Chuck Schumer, a New York Democrat, said earlier this week that he would work to advance cost-cutting measures this spring, which would provide the party a much-needed win ahead of the November midterm elections.